Helen Lau, MD
Endocrinology · Daly City
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 3
- 1 carrier
- Offices
- 4
Offices
4 locations · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Hospitals listed: Ahmc Seton Medical Center · California Pacific Medical Center - Mission Bernal · California Pacific Medical Center- Van Ness Campus · Chinese Hospital · Mills-Peninsula Medical Center. That is not proof they admit you there this week.
Plans that list them
3 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Lau’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
California Medical Board record
Licence A106495 · Current
Licensed to practise in California · since 2009 · expires 2028-08-31 · University of California, Davis School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
5 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Ahmc Seton Medical CenterDaly City, CAAcute Care Hospital · Proprietary · Has an emergency departmentPatients rate it 3 of 5 · 59% would definitely recommend itOverall rating: 1 of 5 starsNo measure marked better or worse than the national rate
- California Pacific Medical Center - Mission BernalSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Church · Has an emergency departmentPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 76% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.322, Oct 2024 – Sep 2025
- California Pacific Medical Center- Van Ness CampusSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 78% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.224, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.325, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.373, Oct 2024 – Sep 2025
- Chinese HospitalSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPatients rate it 3 of 5 · 64% would definitely recommend itOverall rating: 2 of 5 starsNo measure marked better or worse than the national rate
- Peninsula Medical CenterBurlingame, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 78% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.139, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.242, Oct 2024 – Sep 2025
See every measure and the patient survey for Ahmc Seton Medical Center
Behind the star rating — Deaths: 0 better, 6 the same, 0 worse of 6 measures. Safety: 1 better, 2 the same, 0 worse of 3 measures. Readmissions: 0 better, 5 the same, 2 worse of 7 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.98 (0 to 2.04) · 229 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.91 (0.49 to 1.34) | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 7.9 · 34 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 13.4 · 60 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 12.5 · 103 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 18.9 · 159 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 13.9 · 36 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 4.4 · 739 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.19 (0 to 0.41) · 1,636 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.3 (0.09 to 0.51) · 1,681 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.47 (1.02 to 5.93) · 355 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.64 (0 to 3.36) · 44 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.77 (1.1 to 4.43) · 361 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.62 (0 to 18.38) · 43 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.98 (1.71 to 10.25) · 43 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.72 (0.21 to 3.24) · 73 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.3 (0 to 1.23) · 1,387 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.5 · 30 cases | None | Apr 2023 – Mar 2025 |
| Clostridium Difficile (C.Diff)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.9 · 77 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 190 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 22.4 · 53 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 26.4 · 110 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 63.8 · 154 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.9 · 258 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.4 · 53 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13 (9.6 to 17.6) · 48 cases | No different | Jan 2022 – Dec 2024 |
What patients said (257 patients answered, 20% of those asked)
| Cleanliness | 2 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 2 |
| Quietness | 2 |
| Recommend hospital | 3 |
| Room was "always" clean | 59% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 56% |
| Yes, staff "did" give patients this information | 83% |
| Yes, staff "did" give patients information about help after discharge | 81% |
| Doctors "always" explained things so they could understand | 78% |
| Doctors "always" listened carefully | 77% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 59% |
| Staff "always" explained new medications | 68% |
| Nurses "always" explained things so they could understand | 70% |
| Nurses "always" listened carefully | 75% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 44% |
| "YES", patients would definitely recommend the hospital | 59% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for California Pacific Medical Center - Mission Bernal
Behind the star rating — Deaths: 0 better, 5 the same, 0 worse of 5 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 0 better, 3 the same, 3 worse of 6 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.322 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.24 (0.19 to 2.28) · 336 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.87 (0.47 to 1.27) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 163.19 (101.27 to 225.11) · 28 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 8.5 · 44 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.6 · 155 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13.4 · 177 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11.6 · 32 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.2 · 1,281 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.19 (0 to 0.42) · 2,912 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.24 (0.04 to 0.45) · 2,681 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.07 (1.81 to 6.33) · 787 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.61 (0 to 3.31) · 425 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.46 (0.79 to 4.12) · 755 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.36 (0 to 16.38) · 431 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.47 (1.38 to 9.55) · 401 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.7 (0.2 to 3.2) · 105 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.27 (0 to 1.16) · 2,291 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 2.4 · 369 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.602 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.618 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22 · 242 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 20.9 · 197 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 39.6 · 203 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.1 · 292 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.9 · 353 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.9 · 74 cases | None | Jul 2023 – Jun 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.4) · 110 cases | No different | Jan 2024 – Dec 2024 |
What patients said (406 patients answered, 18% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 78% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 60% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 85% |
| Doctors "always" explained things so they could understand | 78% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 74% |
| Staff "always" explained new medications | 74% |
| Nurses "always" explained things so they could understand | 76% |
| Nurses "always" listened carefully | 75% |
| Nurses "always" treated them with courtesy and respect | 83% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 76% |
| Staff "always" explained possible side effects | 47% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
See every measure and the patient survey for California Pacific Medical Center- Van Ness Campus
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 0 better, 8 the same, 2 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.224 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.325 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.373 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.14 (0.3 to 1.97) · 2,271 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.05 (0.81 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 192.86 (151.51 to 234.22) · 140 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 10.3 · 60 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.5 · 143 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.8 · 356 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.3 · 259 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 173 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.1 · 2,316 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.31 (0.12 to 0.49) · 6,430 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.09 to 0.47) · 7,168 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.3 (1.5 to 5.09) · 2,196 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.47 (1.21 to 3.74) · 925 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.63 (1.37 to 3.88) · 1,954 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.13 (6.06 to 14.2) · 1,112 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.26 (4.67 to 9.85) · 1,084 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.67 (0.31 to 3.03) · 832 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.33 (0 to 0.85) · 5,406 cases | No different | Jul 2022 – Jun 2024 |
| MRSA BacteremiaInfections | 0.443 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.717 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.3 · 200 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.3 · 449 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 18.2 · 187 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 8.7 · 418 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 7.1 · 260 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19.2 · 293 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (3.6 to 7.6) · 157 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.2 (7.7 to 13.5) · 157 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for CABGUnplanned return visits | 11 · 33 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.2 · 66 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.5 (9.4 to 16.7) · 551 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.3) · 219 cases | No different | Jan 2024 – Dec 2024 |
What patients said (478 patients answered, 20% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 74% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 59% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 75% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 70% |
| Nurses "always" listened carefully | 71% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
See every measure and the patient survey for Chinese Hospital
Behind the star rating — Deaths: 0 better, 5 the same, 0 worse of 5 measures. Safety: 0 better, 2 the same, 0 worse of 2 measures. Readmissions: 0 better, 7 the same, 1 worse of 8 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.02 (0 to 2.09) · 104 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.12 (0.64 to 1.61) | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 7.3 · 28 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.6 · 71 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.1 · 66 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.7 · 81 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.5 · 569 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0 to 0.44) · 766 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.26 (0.05 to 0.48) · 749 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.34 (0.76 to 5.93) · 96 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.13 (0.4 to 3.85) · 50 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.3 (0.57 to 4.02) · 93 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.72 (0 to 18.54) · 48 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.04 (0.78 to 9.3) · 48 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.07 (0.55 to 3.59) · 58 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 1.12 (0 to 2.33) · 543 cases | No different | Jul 2022 – Jun 2024 |
| Clostridium Difficile (C.Diff)Infections | 0.392 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.7 · 111 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 33 · 78 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 16.3 · 64 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19 · 148 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.1 · 55 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13 (9.7 to 17.1) · 478 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.5) · 39 cases | No different | Jan 2024 – Dec 2024 |
What patients said (160 patients answered, 21% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 3 |
| Recommend hospital | 3 |
| Room was "always" clean | 74% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 78% |
| Staff "always" explained | 68% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 85% |
| Doctors "always" explained things so they could understand | 77% |
| Doctors "always" listened carefully | 73% |
| Doctors "always" treated them with courtesy and respect | 83% |
| Patients who gave a rating of "9" or "10" (high) | 63% |
| Staff "always" explained new medications | 79% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 71% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 55% |
| "YES", patients would definitely recommend the hospital | 64% |
| Staff "always" explained possible side effects | 57% |
| Yes, staff "did" give patients information about possible symptoms | 93% |
See every measure and the patient survey for Peninsula Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.139 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.242 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.21 (0.27 to 2.15) · 1,258 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.81 (0.51 to 1.1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 155.44 (112.67 to 198.21) · 90 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.5 · 32 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 82 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10 · 188 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9 · 473 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.8 · 342 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.4 · 485 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 3,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0 to 0.4) · 6,904 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,052 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.41 (1.43 to 5.39) · 1,695 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.72 (0.17 to 3.28) · 665 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.66 to 3.56) · 1,545 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.1 (1.3 to 12.9) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.96 (2.63 to 9.29) · 653 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.15 to 3.08) · 418 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.14 (0 to 0.78) · 5,539 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.7 · 192 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.215 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.263 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.74 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.3 · 300 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19 · 702 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 1.2 · 207 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -13.6 · 531 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 24.3 · 343 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.1 · 449 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.5 (2.8 to 7) · 85 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 9.6 (6.7 to 13.7) · 85 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.7 · 189 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11 · 45 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.6 · 117 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13 (9.7 to 17.2) · 584 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.2) · 764 cases | No different | Jan 2024 – Dec 2024 |
What patients said (523 patients answered, 27% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 81% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$57,678
Medicare paid this office $57,678 for 205 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 114 | $32,521 | $113 |
| New patient visit (45+ min) | 93 | $12,031 | $129 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 36 | $5,055 | $69 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 95 | $2,292 | $15 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 27 | $2,129 | $30 |
See all 6 services
| Return visit (30+ min) | 114 | $32,521 | $113 |
| New patient visit (45+ min) | 93 | $12,031 | $129 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 36 | $5,055 | $69 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 95 | $2,292 | $15 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 27 | $2,129 | $30 |
| Short return visit (20+ min) | 19 | $1,894 | $82 |
Who their Medicare patients are
205 Original Medicare patients in 2024. Average age 75 · Women 59% · Also on Medicaid 19% · Health risk score 1.59. Above the middle of the specialty; the typical endocrinology clinician is at 1.46.
Conditions among them: High blood pressure 75% · Diabetes 66% · Chronic kidney disease 40% · Coronary heart disease 29% · Atrial fibrillation 22% · Heart failure 21% · Cancer 16% · Depression 15% · Stroke 13% · COPD 12% · Dementia 10%.
The office billed $217,977, Medicare allowed $79,399 and paid $57,678; for 727 services of 13 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 205 | 727 | 75 | 1.59 | $217,977 | $57,678 |
| 2023 | 73 | 117 | 74 | 1.45 | $47,159 | $13,022 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 3 services
| New patient visit (45+ min) | 51 | $7,758 | $152 |
| Return visit (30+ min) | 15 | $1,920 | $120 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 11 | $462 | $31 |
Drugs they prescribed that Part D paid
$1,097,443
Pharmacies billed $1,097,443 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 1,849) in 2024. At or below the middle of the specialty; the typical endocrinology clinician is at 0%.
735 generic and 1,011 brand-name prescriptions · $1,097,443 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Ozempic | 167 | $233,304 | $1,397 |
| Jardiance | 144 | $180,622 | $1,254 |
| Trulicity | 90 | $138,329 | $1,537 |
| Farxiga | 74 | $78,056 | $1,055 |
| Rybelsus | 45 | $74,241 | $1,650 |
See all 34 drugs
| Ozempic | 167 | $233,304 | $1,397 |
| Jardiance | 144 | $180,622 | $1,254 |
| Trulicity | 90 | $138,329 | $1,537 |
| Farxiga | 74 | $78,056 | $1,055 |
| Rybelsus | 45 | $74,241 | $1,650 |
| Mounjaro | 47 | $58,617 | $1,247 |
| Tymlos | 11 | $34,060 | $3,096 |
| Humalog Kwikpen U-200 | 11 | $30,481 | $2,771 |
| Januvia | 24 | $26,322 | $1,097 |
| Toujeo Solostar | 31 | $19,245 | $621 |
| Toujeo Max Solostar | 13 | $14,872 | $1,144 |
| Dapagliflozin | 12 | $9,757 | $813 |
| Nano 2nd Gen Pen Needle | 52 | $8,329 | $160 |
| Humalog Kwikpen U-100 | 17 | $8,071 | $475 |
| Insulin Lispro Kwikpen U-100 | 13 | $5,093 | $392 |
| Basaglar Kwikpen U-100 | 15 | $4,317 | $288 |
| Novolog Flexpen | 21 | $3,853 | $183 |
| Lantus Solostar | 35 | $2,822 | $81 |
| Levothyroxine | 216 | $2,479 | $11 |
| Synthroid | 16 | $1,913 | $120 |
| Metformin | 127 | $1,709 | $13 |
| Metformin Hcl Er | 95 | $1,243 | $13 |
| Acarbose | 16 | $1,123 | $70 |
| Hydrocortisone | 14 | $948 | $68 |
| Methimazole | 56 | $884 | $16 |
| Alendronate | 70 | $701 | $10 |
| Losartan | 27 | $508 | $19 |
| Atorvastatin | 38 | $473 | $12 |
| Liothyronine | 12 | $459 | $38 |
| Ezetimibe | 15 | $401 | $27 |
| Pioglitazone | 18 | $234 | $13 |
| Glipizide | 27 | $202 | $7 |
| Rosuvastatin | 31 | $194 | $6 |
| Fenofibrate | 13 | $36 | $3 |
Year by year
| 2024 | 1,849 | 364 | 0% (0) | 55% | $1,097,443 |
| 2023 | 3,648 | 407 | 0% (0) | 57% | $2,358,335 |
| 2022 | 3,477 | 399 | 0% (0) | 58% | $1,956,908 |
| 2021 | 3,017 | 328 | 0% (0) | 58% | $1,558,544 |
| 2020 | 2,656 | 268 | 0% (0) | 57% | $1,302,892 |
| 2019 | 2,505 | 246 | 0% (0) | 56% | $1,107,082 |
| 2018 | 2,028 | 230 | 0% (0) | 53% | $712,010 |
| 2017 | 1,516 | 186 | 0% (0) | 48% | $407,076 |
| 2016 | 1,372 | 177 | 0% (0) | 48% | $314,709 |
| 2015 | 870 | 115 | 0% (0) | 49% | $183,691 |
| 2014 | 276 | 50 | 0% (0) | 46% | $44,690 |
| 2013 | 85 | 14 | 0% (0) | 24% | $6,731 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 50 drugs
| Ozempic | 345 | $528,829 | $1,533 |
| Trulicity | 209 | $263,822 | $1,262 |
| Jardiance | 193 | $215,807 | $1,118 |
| Farxiga | 192 | $213,679 | $1,113 |
| Rybelsus | 84 | $147,142 | $1,752 |
| Novolog Flexpen | 117 | $138,211 | $1,181 |
| Victoza 3-Pak | 28 | $72,295 | $2,582 |
| Januvia | 51 | $62,738 | $1,230 |
| Humalog Kwikpen U-200 | 17 | $59,089 | $3,476 |
| Prolia | 28 | $47,094 | $1,682 |
| Humalog Kwikpen U-100 | 42 | $43,767 | $1,042 |
| Toujeo Max Solostar | 36 | $38,921 | $1,081 |
| Toujeo Solostar | 63 | $33,710 | $535 |
| Lantus Solostar | 60 | $28,700 | $478 |
| Vascepa | 41 | $25,821 | $630 |
| Mounjaro | 21 | $23,609 | $1,124 |
| Levemir Flexpen | 23 | $20,037 | $871 |
| Soliqua 100-33 | 18 | $18,942 | $1,052 |
| Humalog | 14 | $18,441 | $1,317 |
| Tresiba Flextouch U-100 | 21 | $17,197 | $819 |
| Nano 2nd Gen Pen Needle | 112 | $16,490 | $147 |
| Basaglar Kwikpen U-100 | 35 | $14,117 | $403 |
| Icosapent Ethyl | 22 | $12,818 | $583 |
| Repatha Sureclick | 14 | $10,111 | $722 |
| Lyumjev Kwikpen U-100 | 13 | $10,026 | $771 |
| Levothyroxine | 362 | $5,642 | $16 |
| Metformin | 269 | $5,395 | $20 |
| Insulin Lispro Kwikpen U-100 | 13 | $5,043 | $388 |
| Tirosint-Sol | 18 | $4,852 | $270 |
| Acarbose | 49 | $4,670 | $95 |
| Metformin Hcl Er | 126 | $3,690 | $29 |
| Ultra-Fine Nano Pen Needle | 25 | $2,996 | $120 |
| Pioglitazone | 63 | $2,857 | $45 |
| Alendronate | 117 | $1,849 | $16 |
| Ezetimibe | 42 | $1,733 | $41 |
| Synthroid | 24 | $1,677 | $70 |
| Methimazole | 114 | $1,459 | $13 |
| Atorvastatin | 72 | $1,425 | $20 |
| Rosuvastatin | 47 | $1,247 | $27 |
| Liothyronine | 23 | $740 | $32 |
| Losartan | 45 | $654 | $15 |
| Pravastatin | 27 | $629 | $23 |
| Fenofibrate | 15 | $394 | $26 |
| Gabapentin | 25 | $392 | $16 |
| Hydrochlorothiazide | 19 | $170 | $9 |
| Glipizide | 15 | $164 | $11 |
| Glimepiride | 12 | $142 | $12 |
| Propranolol | 14 | $122 | $9 |
| Lisinopril | 17 | $107 | $6 |
| Simvastatin | 14 | $92 | $7 |
2022: 50 drugs
| Trulicity | 263 | $361,601 | $1,375 |
| Ozempic | 212 | $287,895 | $1,358 |
| Jardiance | 131 | $160,183 | $1,223 |
| Farxiga | 155 | $125,723 | $811 |
| Victoza 3-Pak | 67 | $121,087 | $1,807 |
| Rybelsus | 90 | $107,402 | $1,193 |
| Novolog Flexpen | 117 | $99,118 | $847 |
| Humalog Kwikpen U-200 | 21 | $89,308 | $4,253 |
| Januvia | 68 | $81,458 | $1,198 |
| Prolia | 30 | $45,573 | $1,519 |
| Victoza 2-Pak | 19 | $38,682 | $2,036 |
| Lantus Solostar | 79 | $38,308 | $485 |
| Humalog Kwikpen U-100 | 34 | $30,176 | $888 |
| Levemir Flextouch | 37 | $28,170 | $761 |
| Invokana | 30 | $27,996 | $933 |
| Vascepa | 41 | $22,924 | $559 |
| Toujeo Solostar | 45 | $22,842 | $508 |
| Tresiba Flextouch U-100 | 26 | $20,999 | $808 |
| Toujeo Max Solostar | 12 | $16,560 | $1,380 |
| Lantus | 18 | $13,206 | $734 |
| Nano 2nd Gen Pen Needle | 110 | $13,159 | $120 |
| Basaglar Kwikpen U-100 | 30 | $11,537 | $385 |
| Humalog | 11 | $9,663 | $878 |
| Repatha Sureclick | 16 | $8,316 | $520 |
| Soliqua 100-33 | 11 | $7,994 | $727 |
| Levothyroxine | 361 | $5,945 | $16 |
| Insulin Lispro Kwikpen U-100 | 14 | $4,674 | $334 |
| Acarbose | 74 | $4,353 | $59 |
| Tirosint | 24 | $4,008 | $167 |
| Ultra-Fine Nano Pen Needle | 29 | $3,599 | $124 |
| Metformin | 282 | $3,555 | $13 |
| Pioglitazone | 51 | $3,048 | $60 |
| Testosterone | 12 | $2,227 | $186 |
| Synthroid | 31 | $1,781 | $57 |
| Metformin Hcl Er | 99 | $1,415 | $14 |
| Atorvastatin | 88 | $1,339 | $15 |
| Ezetimibe | 33 | $1,281 | $39 |
| Rosuvastatin | 43 | $1,098 | $26 |
| Losartan | 46 | $1,075 | $23 |
| Repaglinide | 17 | $1,026 | $60 |
| Alendronate | 97 | $976 | $10 |
| Methimazole | 86 | $928 | $11 |
| Fenofibrate | 13 | $677 | $52 |
| Pravastatin | 32 | $565 | $18 |
| Liothyronine | 14 | $455 | $32 |
| Gabapentin | 30 | $439 | $15 |
| Hydrochlorothiazide | 17 | $249 | $15 |
| Glipizide | 12 | $240 | $20 |
| Simvastatin | 15 | $196 | $13 |
| Glimepiride | 13 | $153 | $12 |
2021: 47 drugs
| Trulicity | 272 | $361,982 | $1,331 |
| Ozempic | 152 | $167,276 | $1,101 |
| Victoza 3-Pak | 102 | $153,371 | $1,504 |
| Jardiance | 116 | $117,704 | $1,015 |
| Novolog Flexpen | 81 | $79,887 | $986 |
| Januvia | 68 | $66,857 | $983 |
| Victoza 2-Pak | 37 | $47,331 | $1,279 |
| Lantus Solostar | 96 | $47,289 | $493 |
| Farxiga | 70 | $46,617 | $666 |
| Invokana | 57 | $41,602 | $730 |
| Humalog Kwikpen U-100 | 38 | $39,818 | $1,048 |
| Prolia | 28 | $39,677 | $1,417 |
| Tresiba Flextouch U-200 | 19 | $33,795 | $1,779 |
| Vascepa | 49 | $26,893 | $549 |
| Toujeo Solostar | 56 | $25,029 | $447 |
| Humalog | 15 | $20,198 | $1,347 |
| Tresiba Flextouch U-100 | 28 | $14,450 | $516 |
| Rybelsus | 14 | $13,834 | $988 |
| Nano 2nd Gen Pen Needle | 113 | $12,639 | $112 |
| Insulin Lispro Kwikpen U-100 | 28 | $11,664 | $417 |
| Levemir Flextouch | 17 | $9,951 | $585 |
| Lantus | 11 | $8,640 | $785 |
| Basaglar Kwikpen U-100 | 18 | $7,358 | $409 |
| Praluent | 14 | $6,731 | $481 |
| Repatha Sureclick | 14 | $6,637 | $474 |
| Acarbose | 86 | $5,778 | $67 |
| Levothyroxine | 284 | $5,587 | $20 |
| Ultra-Fine Nano Pen Needle | 29 | $3,686 | $127 |
| Metformin | 244 | $2,531 | $10 |
| Tirosint | 16 | $2,268 | $142 |
| Rosuvastatin | 30 | $1,966 | $66 |
| Synthroid | 30 | $1,495 | $50 |
| Metformin Hcl Er | 68 | $1,406 | $21 |
| Testosterone | 13 | $1,349 | $104 |
| Atorvastatin | 85 | $1,293 | $15 |
| Ezetimibe | 22 | $1,108 | $50 |
| Pioglitazone | 38 | $1,062 | $28 |
| Methimazole | 81 | $983 | $12 |
| Losartan | 40 | $801 | $20 |
| Alendronate | 69 | $637 | $9 |
| Fenofibrate | 12 | $498 | $41 |
| Pravastatin | 22 | $482 | $22 |
| Gabapentin | 21 | $316 | $15 |
| Simvastatin | 22 | $241 | $11 |
| Glipizide | 19 | $181 | $10 |
| Glimepiride | 27 | $152 | $6 |
| Hydrochlorothiazide | 17 | $146 | $9 |
2020: 46 drugs
| Trulicity | 290 | $327,504 | $1,129 |
| Victoza 3-Pak | 132 | $186,359 | $1,412 |
| Jardiance | 106 | $98,977 | $934 |
| Ozempic | 94 | $97,234 | $1,034 |
| Humalog Kwikpen U-100 | 71 | $66,726 | $940 |
| Novolog Flexpen | 58 | $54,241 | $935 |
| Lantus Solostar | 88 | $48,194 | $548 |
| Tresiba Flextouch U-200 | 36 | $45,149 | $1,254 |
| Januvia | 58 | $44,068 | $760 |
| Invokana | 54 | $42,192 | $781 |
| Toujeo Solostar | 58 | $26,744 | $461 |
| Prolia | 20 | $25,986 | $1,299 |
| Farxiga | 32 | $22,068 | $690 |
| Vascepa | 49 | $20,104 | $410 |
| Victoza 2-Pak | 19 | $18,296 | $963 |
| Tresiba Flextouch U-100 | 22 | $13,461 | $612 |
| Ultra-Fine Nano Pen Needle | 102 | $10,522 | $103 |
| Insulin Lispro Kwikpen U-100 | 20 | $9,788 | $489 |
| Levemir Flextouch | 14 | $8,027 | $573 |
| Repatha Sureclick | 17 | $7,682 | $452 |
| Janumet Xr | 13 | $6,349 | $488 |
| Levothyroxine | 244 | $5,820 | $24 |
| Acarbose | 72 | $5,153 | $72 |
| Testosterone | 17 | $3,506 | $206 |
| Nano 2nd Gen Pen Needle | 36 | $3,487 | $97 |
| Metformin | 205 | $2,111 | $10 |
| Metformin Hcl Er | 68 | $1,373 | $20 |
| Synthroid | 23 | $1,182 | $51 |
| Pioglitazone | 42 | $1,155 | $28 |
| Rosuvastatin | 27 | $1,097 | $41 |
| Atorvastatin | 44 | $1,069 | $24 |
| Ultra-Fine Short Pen Needle | 14 | $1,067 | $76 |
| Ezetimibe | 18 | $661 | $37 |
| Losartan | 38 | $609 | $16 |
| Metoprolol | 18 | $598 | $33 |
| Pravastatin | 24 | $590 | $25 |
| Alendronate | 59 | $555 | $9 |
| Pregabalin | 11 | $494 | $45 |
| Methimazole | 28 | $458 | $16 |
| Calcitriol | 12 | $457 | $38 |
| Fenofibrate | 14 | $349 | $25 |
| Simvastatin | 25 | $263 | $11 |
| Gabapentin | 14 | $134 | $10 |
| Glipizide | 15 | $108 | $7 |
| Glimepiride | 21 | $81 | $4 |
| Alcohol Swab | 13 | $11 | $1 |
2019: 44 drugs
| Trulicity | 252 | $248,393 | $986 |
| Victoza 3-Pak | 136 | $165,162 | $1,214 |
| Jardiance | 143 | $112,078 | $784 |
| Humalog Kwikpen U-100 | 108 | $89,751 | $831 |
| Victoza 2-Pak | 79 | $71,509 | $905 |
| Lantus Solostar | 73 | $39,131 | $536 |
| Novolog Flexpen | 55 | $39,097 | $711 |
| Januvia | 39 | $35,770 | $917 |
| Toujeo Solostar | 48 | $31,882 | $664 |
| Ozempic | 28 | $25,497 | $911 |
| Prolia | 16 | $19,728 | $1,233 |
| Invokana | 16 | $16,692 | $1,043 |
| Tresiba Flextouch U-200 | 13 | $15,586 | $1,199 |
| Tradjenta | 23 | $14,722 | $640 |
| Farxiga | 15 | $11,296 | $753 |
| Ultra-Fine Nano Pen Needle | 110 | $11,259 | $102 |
| Levemir Flextouch | 14 | $10,058 | $718 |
| Basaglar Kwikpen U-100 | 15 | $6,315 | $421 |
| Tresiba Flextouch U-100 | 13 | $6,139 | $472 |
| Acarbose | 83 | $5,941 | $72 |
| Janumet Xr | 12 | $5,463 | $455 |
| Levothyroxine | 203 | $4,710 | $23 |
| Vascepa | 12 | $4,395 | $366 |
| Metformin | 218 | $2,439 | $11 |
| Metformin Hcl Er | 53 | $1,764 | $33 |
| Atorvastatin | 61 | $1,731 | $28 |
| Rosuvastatin | 19 | $1,438 | $76 |
| Ultra-Fine Short Pen Needle | 13 | $1,349 | $104 |
| Synthroid | 26 | $1,298 | $50 |
| Pioglitazone | 42 | $1,142 | $27 |
| Ezetimibe | 17 | $987 | $58 |
| Losartan | 60 | $966 | $16 |
| Metoprolol | 16 | $805 | $50 |
| Calcitriol | 19 | $571 | $30 |
| Alendronate | 45 | $455 | $10 |
| Methimazole | 21 | $438 | $21 |
| Simvastatin | 33 | $420 | $13 |
| Fenofibrate | 15 | $388 | $26 |
| Gabapentin | 17 | $333 | $20 |
| Pravastatin | 21 | $308 | $15 |
| Glimepiride | 22 | $241 | $11 |
| Diltiazem 24hr Er (La) | 12 | $240 | $20 |
| Glipizide | 24 | $180 | $7 |
| Lisinopril | 12 | $121 | $10 |
2018: 35 drugs
| Trulicity | 119 | $120,789 | $1,015 |
| Jardiance | 110 | $79,898 | $726 |
| Victoza 3-Pak | 68 | $75,908 | $1,116 |
| Humalog Kwikpen U-100 | 94 | $73,439 | $781 |
| Victoza 2-Pak | 86 | $62,865 | $731 |
| Tradjenta | 51 | $34,669 | $680 |
| Januvia | 28 | $29,219 | $1,044 |
| Novolog Flexpen | 47 | $27,854 | $593 |
| Tresiba Flextouch U-200 | 14 | $21,573 | $1,541 |
| Invokana | 22 | $21,122 | $960 |
| Toujeo Solostar | 37 | $20,717 | $560 |
| Lantus Solostar | 32 | $15,596 | $487 |
| Prolia | 12 | $14,100 | $1,175 |
| Farxiga | 21 | $13,365 | $636 |
| Basaglar Kwikpen U-100 | 22 | $10,631 | $483 |
| Ultra-Fine Nano Pen Needle | 111 | $9,911 | $89 |
| Tresiba Flextouch U-100 | 20 | $9,536 | $477 |
| Levothyroxine | 229 | $4,965 | $22 |
| Acarbose | 62 | $4,433 | $71 |
| Atorvastatin | 59 | $2,417 | $41 |
| Metformin | 186 | $2,173 | $12 |
| Synthroid | 51 | $2,162 | $42 |
| Pioglitazone | 46 | $1,175 | $26 |
| Metoprolol | 17 | $1,171 | $69 |
| Rosuvastatin | 16 | $910 | $57 |
| Pravastatin | 36 | $768 | $21 |
| Metformin Hcl Er | 36 | $768 | $21 |
| Ezetimibe | 11 | $760 | $69 |
| Losartan | 57 | $629 | $11 |
| Methimazole | 34 | $446 | $13 |
| Simvastatin | 21 | $284 | $14 |
| Gabapentin | 18 | $257 | $14 |
| Alendronate | 15 | $213 | $14 |
| Glipizide | 12 | $102 | $8 |
| Hydrochlorothiazide | 11 | $86 | $8 |
2017: 30 drugs
| Humalog Kwikpen U-100 | 74 | $50,475 | $682 |
| Januvia | 59 | $43,217 | $732 |
| Novolog Flexpen | 47 | $30,739 | $654 |
| Jardiance | 45 | $30,131 | $670 |
| Trulicity | 28 | $23,287 | $832 |
| Toujeo Solostar | 49 | $21,347 | $436 |
| Lantus Solostar | 44 | $20,757 | $472 |
| Invokana | 35 | $20,139 | $575 |
| Tradjenta | 29 | $20,112 | $694 |
| Farxiga | 24 | $16,547 | $689 |
| Victoza 3-Pak | 12 | $10,919 | $910 |
| Onglyza | 14 | $10,681 | $763 |
| Victoza 2-Pak | 13 | $10,558 | $812 |
| Levemir Flextouch | 21 | $9,995 | $476 |
| Ultra-Fine Nano Pen Needle | 79 | $7,408 | $94 |
| Metformin Hcl Er | 28 | $5,329 | $190 |
| Acarbose | 80 | $4,369 | $55 |
| Levothyroxine | 155 | $3,844 | $25 |
| Atorvastatin | 72 | $1,960 | $27 |
| Pioglitazone | 70 | $1,639 | $23 |
| Metformin | 122 | $1,464 | $12 |
| Synthroid | 20 | $1,279 | $64 |
| Losartan | 50 | $591 | $12 |
| Pravastatin | 24 | $464 | $19 |
| Metoprolol | 19 | $459 | $24 |
| Methimazole | 22 | $294 | $13 |
| Glimepiride | 24 | $262 | $11 |
| Simvastatin | 16 | $170 | $11 |
| Glipizide | 11 | $147 | $13 |
| Amlodipine Besylate | 18 | $72 | $4 |
2016: 27 drugs
| Januvia | 83 | $52,957 | $638 |
| Humalog Kwikpen U-100 | 69 | $38,928 | $564 |
| Novolog Flexpen | 48 | $27,109 | $565 |
| Lantus Solostar | 52 | $23,216 | $446 |
| Toujeo Solostar | 49 | $22,240 | $454 |
| Tradjenta | 26 | $17,044 | $656 |
| Onglyza | 22 | $14,760 | $671 |
| Levemir Flextouch | 23 | $10,739 | $467 |
| Invokana | 17 | $9,258 | $545 |
| Novolog | 15 | $8,768 | $585 |
| Bd Ultra-Fine Pen Needle | 90 | $7,346 | $82 |
| Farxiga | 13 | $5,819 | $448 |
| Metformin Hcl Er | 16 | $5,552 | $347 |
| Acarbose | 79 | $4,835 | $61 |
| Levothyroxine | 163 | $4,309 | $26 |
| Pioglitazone | 66 | $1,637 | $25 |
| Valsartan | 13 | $1,637 | $126 |
| Atorvastatin | 58 | $968 | $17 |
| Glimepiride | 41 | $672 | $16 |
| Metformin | 79 | $633 | $8 |
| Losartan | 37 | $377 | $10 |
| Methimazole | 31 | $352 | $11 |
| Simvastatin | 16 | $171 | $11 |
| Lisinopril | 19 | $114 | $6 |
| Alendronate | 13 | $86 | $7 |
| Metoprolol | 15 | $58 | $4 |
| Amlodipine Besylate | 14 | $44 | $3 |
2015: 19 drugs
| Januvia | 52 | $29,982 | $577 |
| Lantus Solostar | 52 | $23,776 | $457 |
| Humalog Kwikpen U-100 | 38 | $23,182 | $610 |
| Novolog Flexpen | 25 | $14,551 | $582 |
| Tradjenta | 23 | $12,166 | $529 |
| Invokana | 23 | $10,193 | $443 |
| Metformin Hcl Er | 33 | $8,113 | $246 |
| Onglyza | 18 | $7,052 | $392 |
| Bd Ultra-Fine Pen Needle | 71 | $4,892 | $69 |
| Acarbose | 51 | $3,027 | $59 |
| Levothyroxine | 103 | $2,226 | $22 |
| Atorvastatin | 43 | $842 | $20 |
| Pioglitazone | 24 | $787 | $33 |
| Glimepiride | 41 | $464 | $11 |
| Methimazole | 24 | $456 | $19 |
| Metformin | 46 | $264 | $6 |
| Losartan | 19 | $171 | $9 |
| Lisinopril | 19 | $92 | $5 |
| Atenolol | 16 | $92 | $6 |
2014: 10 drugs
| Lantus Solostar | 16 | $8,310 | $519 |
| Januvia | 11 | $6,006 | $546 |
| Invokana | 13 | $5,581 | $429 |
| Tradjenta | 11 | $3,313 | $301 |
| Acarbose | 20 | $917 | $46 |
| Bd Ultra-Fine Pen Needle | 15 | $621 | $41 |
| Levothyroxine | 33 | $567 | $17 |
| Glimepiride | 28 | $207 | $7 |
| Atorvastatin | 14 | $189 | $13 |
| Metformin | 23 | $142 | $6 |
2013: 1 drug
| Levothyroxine | 31 | $358 | $12 |
Money from drug and device companies
$83 in 2024
| 2024 | 2 | 2 | None | $83 |
| 2023 | 22 | 82 | None | $1,580 |
| 2022 | 26 | 122 | None | $2,429 |
| 2021 | 19 | 59 | None | $1,226 |
| 2020 | 15 | 36 | None | $832 |
| 2019 | 27 | 135 | None | $2,478 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Beta Bionics | Ilet Bionic Pancreas | $56 | 1 payment
|
| Amgen | Tepezza | $27 | 1 payment
|
See all 2 published payments
| Beta Bionics | Meals · 2024-07-09 | Ilet Bionic Pancreas | $56 |
| Amgen | Meals · 2024-04-17 | Tepezza | $27 |
See earlier years (2023, 2022, 2021, 2020, 2019)
2023: $1,580
| Novo Nordisk | Rybelsus | $329 | 28 payments
|
| Amgen | Evenity | $199 | 9 payments
|
| Bayer Healthcare Pharmaceuticals | Kerendia | $166 | 7 payments
|
| Lilly USA | Mounjaro | $135 | 5 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $129 | 7 payments
|
| MannKind | Afrezza | $80 | 3 payments
|
| Dexcom | Dexcom G6 Transmitter | $71 | 2 payments
|
| Novartis Pharmaceuticals | Leqvio | $51 | 2 payments
|
| Antares Pharma | Nocdurna | $48 | 2 payments
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $46 | 2 payments
|
| Kyowa Kirin | Crysvita | $45 | 2 payments
|
| Esperion Therapeutics | Nexletol | $38 | 2 payments
|
| CeQur | Cequr Simplicity | $37 | 1 payment
|
| Sanofi-Aventis U.S. | Tzield | $30 | 1 payment
|
| Alexion Pharmaceuticals | Strensiq | $24 | 1 payment
|
| Insulet | Omnipod | $24 | 1 payment
|
| Amryt Pharma Holdings | Mycapssa | $23 | 1 payment
|
| Abbott Laboratories | Freestyle Libre 3 | $23 | 1 payment
|
| Horizon Therapeutics plc | Tepezza | $23 | 1 payment
|
| Radius Health | Tymlos | $23 | 1 payment
|
| Abbvie | Synthroid | $20 | 1 payment
|
| Corcept Therapeutics | Korlym | $17 | 1 payment
|
2022: $2,429
| Novo Nordisk | Ozempic | $418 | 39 payments
|
| Lilly USA | Mounjaro | $379 | 15 payments
|
| Amgen | Evenity | $316 | 13 payments
|
| Bayer HealthCare Pharmaceuticals | Kerendia | $239 | 9 payments
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $222 | 10 payments
|
| Insulet | Omnipod | $79 | 3 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $78 | 3 payments
|
| Dexcom | Dexcom G6 Transmitter | $78 | 3 payments
|
| Esperion Therapeutics | Nexletol | $68 | 3 payments
|
| Abbvie | Synthroid | $62 | 3 payments
|
| Mannkind | Afrezza | $56 | 2 payments
|
| Corcept Therapeutics | Korlym | $49 | 2 payments
|
| Horizon Therapeutics plc | Tepezza | $45 | 2 payments
|
| Abbott Laboratories | Freestyle Libre 2 | $45 | 2 payments
|
| Xeris Pharmaceuticals | Gvoke Pfs | $37 | 2 payments
|
| Radius Health | Tymlos | $28 | 1 payment
|
| Antares Pharma | Nocdurna | $28 | 1 payment
|
| Novartis Pharmaceuticals | Leqvio | $25 | 1 payment
|
| Tandem Diabetes Care | T:Slim X2 Insulin Pump With Control-Iq | $24 | 1 payment
|
| Becton Dickinson and | Bd Nano 2nd Gen Pen Needle | $24 | 1 payment
|
| Sanofi-Aventis U.S. | Soliqua 100/33 | $23 | 1 payment
|
| Vivus | Qsymia | $22 | 1 payment
|
| Recordati Rare Diseases Inc. | Signifor Lar | $21 | 1 payment
|
| EUSA Pharma (US) | Sylvant | $21 | 1 payment
|
| Merck Sharp & Dohme | Januvia | $21 | 1 payment
|
| Amarin Pharma | Vascepa | $21 | 1 payment
|
2021: $1,226
| Lilly USA | Trulicity | $306 | 12 payments
|
| Novo Nordisk | Ozempic | $221 | 17 payments
|
| Esperion Therapeutics | Nexletol | $88 | 4 payments
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $85 | 4 payments
|
| Amgen | Evenity | $80 | 3 payments
|
| Amarin Pharma | Vascepa | $67 | 3 payments
|
| Corcept Therapeutics | Korlym | $50 | 2 payments
|
| Becton Dickinson and | Bd Nano | $46 | 2 payments
|
| Sanofi-Aventis U.S. | Toujeo | $44 | 2 payments
|
| Bigfoot Biomedical | Unity Diabetes Management System | $35 | 1 payment
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $29 | 1 payment
|
| AbbVie | Synthroid | $27 | 1 payment
|
| Bayer HealthCare Pharmaceuticals | Kerendia | $27 | 1 payment
|
| Dexcom | Dexcom G6 Transmitter | $22 | 1 payment
|
| Radius Health | Tymlos | $22 | 1 payment
|
| Zealand Pharma US | Zegalogue | $22 | 1 payment
|
| Medtronic | Inpen | $20 | 1 payment
|
| Xeris Pharmaceuticals | Gvoke Pfs | $19 | 1 payment
|
| MannKind | Afrezza | $17 | 1 payment
|
2020: $832
| Janssen Pharmaceuticals | Invokana | $159 | 7 payments
|
| Lilly USA | Trulicity | $105 | 5 payments
|
| Amarin Pharma | Vascepa | $83 | 4 payments
|
| Amgen | Repatha | $70 | 3 payments
|
| Corcept Therapeutics | Korlym | $67 | 2 payments
|
| Sanofi-Aventis U.S. | Soliqua 100/33 | $56 | 3 payments
|
| IBSA Pharma | Tirosint | $52 | 2 payments
|
| Horizon Therapeutics plc | Tepezza | $42 | 2 payments
|
| Mannkind | Afrezza | $40 | 2 payments
|
| Insulet | Omnipod | $37 | 1 payment
|
| Radius Health | Tymlos | $30 | 1 payment
|
| Medtronic MiniMed | Minilink Real-Time Transmitter | $25 | 1 payment
|
| Novo Nordisk | Ozempic | $24 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $23 | 1 payment
|
| LifeScan | Ot Verio Flex Starter Kit | $19 | 1 payment
|
2019: $2,478
| Novo Nordisk | Ozempic | $462 | 33 payments
|
| Lilly USA | Trulicity | $331 | 19 payments
|
| Amgen | Evenity | $226 | 9 payments
|
| Sanofi-Aventis U.S. | Toujeo | $205 | 11 payments
|
| Insulet | Omnipod | $166 | 6 payments
|
| Janssen Pharmaceuticals | Invokana | $161 | 9 payments
|
| Merck Sharp & Dohme | Januvia | $115 | 7 payments
|
| Shire North American Group | Natpara (Parathyroid Hormone) | $96 | 5 payments
|
| Regeneron Healthcare Solutions | Praluent | $93 | 3 payments
|
| Boehringer Ingelheim Pharmaceuticals | Tradjenta | $59 | 2 payments
|
| Radius Health | Tymlos | $53 | 2 payments
|
| Mannkind | Afrezza | $48 | 3 payments
|
| IBSA Pharma | Tirosint | $47 | 2 payments
|
| Abbott Laboratories | Freestyle Libre Pro | $42 | 3 payments
|
| Theratechnologies | Egrifta | $40 | 2 payments
|
| Corcept Therapeutics | Korlym | $39 | 2 payments
|
| Nalpropion Pharmaceuticals | Contrave | $38 | 2 payments
|
| Companion Medical | Inpen | $37 | 3 payments
|
| Relypsa | Veltassa | $36 | 2 payments
|
| Dexcom | Dexcom Cgm | $32 | 1 payment
|
| Alexion Pharmaceuticals | Strensiq | $31 | 2 payments
|
| Amarin Pharma | Vascepa | $29 | 2 payments
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $23 | 1 payment
|
| Vivus | Qsymia | $22 | 1 payment
|
| AbbVie | Synthroid | $20 | 1 payment
|
| Medtronic MiniMed | Minilink Real-Time Transmitter | $15 | 1 payment
|
| Aegerion Pharmaceuticals | Myalept | $12 | 1 payment
|
Professional record
- NPI
- 1235452871
- Licence
- CA A106495California A106495: Current · expires 2028-08-31
- Trained
- University of California, Davis School of Medicine, 2007
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RE0101X (207RE0101X)
- Mailing address
- 325 Distel Cir, Los Altos, CA, 94022
- NPI first listed
- 2010-03-10
- NPI last updated
- 2023-08-25
- NPI record certified
- 2023-08-25
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 1580 Valencia St Ste 504, San Francisco, CA, 94110
This office lists an electronic records connection.